Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
139 hedge funds and large institutions have $1.11B invested in Alder Biopharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 49 reducing their positions, and 17 closing their positions.
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
24% more capital invested
Capital invested by funds: $893M → $1.11B (+$213M)
3% more funds holding
Funds holding: 135 → 139 (+4)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
22% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 49
87% less call options, than puts
Call options by funds: $1.88M | Put options by funds: $14.6M
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22.7M |
| 2 |
SC
Samlyn Capital
New York
|
+$16.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.8M |
| 4 |
LPC
Lion Point Capital
New York
|
+$8.84M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.5M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$14.7M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$11.2M |
| 3 |
Axa
Paris,
France
|
-$8.18M |
| 4 |
BlackRock
New York
|
-$6.98M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.59M |
ALDR Hedge Fund Activity: Q2 2018 in Review
139 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2018, worth a combined $1.11B — up 24% from $893M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ALDR positions and 17 closed out — a net gain of 5 holders — while 38 added to existing stakes and 49 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $22.7M. The largest seller was State Street, cutting an estimated $14.7M.
- 139 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2018, up from 135 in Q1 2018.
- Funds reported $1.11B of Alder Biopharmaceuticals stock for Q2 2018, up 24% quarter-over-quarter.
- 22 funds opened new Alder Biopharmaceuticals positions in Q2 2018 and 17 closed out, a net change of +5 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2018 was Citadel Advisors, an estimated $22.7M added.
- The largest Alder Biopharmaceuticals seller in Q2 2018 was State Street, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2018.